Loosening Medicaid restrictions on hep C drugs could improve patient access, study finds

While state Medicaid programs have increasingly loosened coverage restrictions on hepatitis C drugs in recent years, a team of researchers at Harvard University recently published a study finding that a further easing of restrictions could improve uptake.

In a paper published in JAMA on Friday, the researchers examined 39 Medicaid programs between 2015 and 2020, 32 of which eased restrictions on direct-acting antivirals to treat hepatitis C. Medicaid programs had initially set restrictions on coverage of the antivirals because they were expensive, but over the years coverage has expanded as prices have come down and in response to litigation and advocacy.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。